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Abstract
Antibody detection assays have long been the first line test to confirm infection with the zoonotic 
parasite Toxoplasma gondii. However, challenges exist with serological diagnosis, especially 
distinguishing between acute, latent and reactivation disease states. The sensitivity and specificity 
of serological tests might be improved by testing for antibodies against parasite antigens other than 
those typically found on the parasite surface during the acute stage. To this end, we analyzed the 
reactivity profile of human sera, identified as positive for anti-T. gondii IgG in traditional assays, 
by indirect immunofluorescence reactivity to acute stage intracellular tachyzoites and in vitro-
induced latent stage bradyzoites. The majority of anti-T. gondii IgG positive sera recognized both 
intracellularly replicating tachyzoites and in vitro-induced bradyzoites with varying patterns of 
immune-reactivity. Furthermore, anti-bradyzoite antibodies were not detected in sera that were 
IgM-positive/IgG-negative. These results demonstrate that anti-T. gondii-positive sera may contain 
antibodies to a variety of antigens in addition to those traditionally used in serological tests, and 
suggest the need for further investigations into the utility of anti-bradyzoite-specific antibodies to 
aid in diagnosis of T. gondii infection.
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1. Introduction
Toxoplasmosis is a parasitic infection caused by the protozoan Toxoplasma gondii. Infection 
may be acquired through ingestion of infective oocysts shed in feline stool or tissue cysts in 
raw or undercooked meat of chronically infected animals. Infection may also be transmitted 
vertically by organ transplantation or in utero. During its life cycle, the parasite transitions 
between stages with differing replicative, metabolic, antigenic and transmissive properties 
(Dubey, 1998; Bohne et al., 1999; Weiss and Kim, 2000; Gross et al., 2004; Skariah et al., 
2010). In the gastrointestinal tract of the definitive host (any feline), the parasite undergoes 
sexual replication with differentiation into macro- and microgametocytes, and the 
development of sporozoites in oocysts, which are shed in the feces and are stable in the 
environment. After oocysts are ingested by an intermediate host (non-feline warm-blooded 
animal), sporozoites are released and the parasite develops into two forms: tachyzoite and 
bradyzoite. The tachyzoite is the rapidly replicating, pathogenic stage associated with 
manifestations of acute disease. Symptoms of acute infection are typically mild in the 
immune-competent host. However, immune-suppressed individuals are at risk of severe 
disease and fatal outcomes (Halonen and Weiss, 2013; Jones et al., 2014). Chronic infection 
occurs due to parasite stage conversion from tachyzoite to bradyzoite, a slowly replicative 
cell type which survives for long periods in the intermediate host. Bradyzoite conversion is 
induced by multiple factors including the host immune response, host cell type and 
metabolism, and the parasite strain (Fux et al., 2007; Ferreira-da-Silva et al., 2008; 
Weilhammer et al., 2012; Swierzy and Lüder, 2015). While humans can be infected with any 
of the three major stages (sporozoites, tachyzoites, bradyzoites), serological assays cleared 
by the United States Food and Drug Administration (FDA) target tachyzoite stage antigens 
(Boothroyd, 2009) (Supplementary Table S1).
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Diagnostic methods for toxoplasmosis include isolation and cultivation of the parasite in an 
animal model or tissue culture, detection of a serological response to infection, histology 
and, more recently, molecular detection of parasite-specific nucleic acid (Jorgensen and 
Pfaller, 2015). Drawbacks to these methods include invasive procedures required to sample 
potentially infected tissue, the cost of maintaining animals or tissue cultures, and a lack of 
FDA approved tests for molecular detection. Thus, serological detection of parasite-specific 
antibodies is typically performed to test for exposure to the parasite, and a negative 
serological result is thought to exclude the possibility of infection (Montoya, 2002; Press et 
al., 2005).
A challenge related to serological diagnosis is the difficulty in distinguishing between acute 
and latent or chronic infection. This is important in guiding the treatment of pregnant 
women due to the risk of congenital transmission during acute infection. While IgM is 
typically associated with acute infection, it may not be detected in some acutely-infected 
individuals and may persist for long periods in others (Fricker-Hidalgo et al., 2013; Beal et 
al., 2014). Another drawback for IgM testing is the potential for false-positive results 
(Wilson et al., 1997; Garry et al., 2005). The FDA issued a public health advisory regarding 
Toxoplasma IgM commercial kits in 1997, which included recommendations for follow-up 
testing at a laboratory with specialized experience in Toxoplasma serological testing 
(Burlington, 1997). Avidity testing is currently recommended to aid in the timing of 
infection for IgG/IgM-positive pregnant individuals (Jorgensen and Pfaller, 2015). High 
avidity IgG, typically found in past infections, is useful for ruling out recent infection. 
However, low avidity IgG, which should be found only in acute or recent infection, has been 
found to persist long-term in some individuals; this confounds the clinical picture if a single 
sample is tested (Findal et al., 2015).
One of the major parasite antigens recognized by the human immune system is the surface 
protein SAG1/p30 (Kasper et al., 1983; Santoro et al., 1985). Accordingly, commercially 
available serology assays test for antibodies (IgG, IgM) to major surface antigens of the 
tachyzoite (Supplementary Table S1). Since T. gondii is an obligate intracellular pathogen, 
many antigens are produced during replication within the host cell and are exposed to the 
immune system upon host cell lysis. Whether antibodies against other antigens play a role in 
the humoral response against Toxoplasma, especially putative ones from intracellularly 
replicating tachyzoites and latent bradyzoites, is under-explored. To investigate this 
possibility, we tested human sera positive for anti-T. gondii antibodies by an immune-
fluorescence assay for immune-reactivity to intracellularly replicating tachyzoites and in 
vitro switched bradyzoites. Our results demonstrate that anti-T. gondii-positive sera may 
contain antibodies to a variety of antigens in addition to those traditionally used in 
serological tests. The detection of antibodies to parasite structures found in host cells 
infected with tachyzoites and bradyzoites opens new avenues to investigation of the humoral 
response to Toxoplasma infection.
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2. Materials and methods
2.1. Serum samples
Samples used in this study were remnants of human sera that had been tested at the Indiana 
University (IU)Health Pathology laboratory (IUHPL), USA for IgG to T. gondii by enzyme-
linked fluorescent assay (ELFA) (n = 89 study samples of 818 clinical samples tested in 
2014) (Vidas, bioMérieux, Durham, NC, USA) and for IgM by an IFA (n = 18 study 
samples of 341 clinical samples tested) (Hemagen Diagnostics, Columbia, MD, USA) by 
routine laboratory protocols and stored at -20°C. Two study specimens were positive for 
both IgG and IgM. Sample selection criteria were IgG and/or IgM positivity, availability of 
stored specimen and sufficient residual volume (≥0.25 ml). Clinical laboratory test results 
were recorded with patient age and gender, and samples were de-identified for further 
investigations. This study was granted exempt status upon protocol review by the Indiana 
University School of Medicine Institutional Review Board (IRB).
2.2. Host cell and parasite maintenance and reagents
Human foreskin fibroblasts (HFF, purchased from American Type Culture Collection 
(ATCC), Manassas, VA, USA)) were grown in DMEM supplemented with 10% fetal bovine 
serum (FBS), 2 mM L-glutamine, and 100 units of penicillin/100 μg of streptomycin per 
mL, in a humidified incubator at 37°C and 5% CO2. Green monkey kidney cells (Vero) were 
grown under the same conditions. Parasite strains were maintained by passage through HFFs 
in normal culture medium and grown in Vero cells for all studies using human sera. All 
experiments were performed with T. gondii strain PRUΔC32 (Singh et al., 2002). This strain 
carries GFP under the control of the bradyzoite stage-specific ldh2 promoter.
2.3. Immunofluorescence assays and western blots
For IFA, 1×104 PRUΔC32 tachyzoites were inoculated into Vero cells oncoverslips for IFA. 
After 35 h of incubation, coverslips were fixed with 4% paraformaldehyde, and an IFA was 
performed using a routine laboratory protocol (Arrizabalaga et al., 2004). The primary 
antibody was the human serum (1:500 for IgG sero-positive specimens, 1:20 for IgM sero-
positive specimens) and the secondary antibody was Alexa-fluor 594 conjugated goat anti-
human IgG or anti-human IgM (1:2000 for both classes) (ThermoFisher Scientific, Waltham, 
MA, USA). DAPI (1:1000) was used to stain nuclear material. In vitro bradyzoites were 
induced with alkaline stress (RPMI pH 8.2) incubation for 4–5 days in an ambient-air 
incubator (Weiss et al., 1995) and IFA performed as for tachyzoites. Slides were examined in 
a zig-zag pattern on a Nikon microscope at 600× total magnification. For each serum sample 
tested, photomicrographs were taken from three fields of view with parasitic structures 
observable by phase contrast microscopy. Sera were classified as positive for anti-
Toxoplasma antibody if specific signal was observed for parasite-associated structures as 
identified by phase contrast. Staining patterns were compared with previously published 
patterns for different parasite antigens (cyst wall (Tobin et al., 2010), matrix (Zhang et al., 
1999), bradyzoite surface (Saeij et al., 2008), parasitophorous vacuole (PV) membrane 
(PVM) (Karsten et al., 1998), surface antigen 1 (SAG1), PV-internal structures/intravacuolar 
network (IVN) (Rome et al., 2008). For in vitro bradyzoites, only GFP-positive structures 
were imaged. The 4 μm scale bar was determined from the narrowest (non-dividing) 
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tachyzoite or bradyzoite cell width (reported as approximately 2 μm (Dubey et al., 1998)) in 
each image and doubling the measurement.
Co-localization experiments were performed with human serum and mouse anti-SAG1 
(Genway Inc., San Diego, CA, USA), mouse anti-GRA7 (dense granule antigen 7, (Coppens 
et al., 2006)) for intracellular tachyzoites, and mouse anti-BAG1 (bradyzoite antigen 1, 
Weiss et al., 1992; McAllister et al., 1996) antibodies and Dolichos biflorus agglutinin 
(lectin that recognizes cyst wall, Vectorlabs Inc., Burlingame, CA, USA).
For western blots, extracellular parasites were filtered, washed in PBS, and pelleted by 
centrifugation. The parasite cell pellet was lysed in SDS sample buffer with a final 
concentration of 5×107 tachyzoites/ml. Vero cells were trypsinized, centrifuged, washed 
with PBS, and lysed in SDS sample buffer at a final concentration of 5×106 cells/ml. Ten μl 
of each lysate were used for western blot per routine laboratory protocol (Garrison and 
Arrizabalaga, 2009); primary antibody was IgG sero-positive human serum or anti-SAG1-
positive or -negative mouse serum (1:5000) and the secondary antibody was horseradish 
peroxidase (HRP)-conjugated goat anti-human IgG or Goat anti-mouse IgG (1:20,000) 
(Thermo Fisher Scientific). Chemiluminescent substrate (SuperSignal West Femto Substrate, 
Thermo Fisher Scientific) was applied to the membranes and signal detected by a myECL 
Imager (Thermo Fisher Scientific).
2.4. Toxoplasma gondii serology assays commercially available in the U.S
The U.S. FDA in vitro diagnostic device database, Device@FDA, website (http://
www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm) was queried for “Toxoplasma” 
and the resulting table listing FDA documents was exported into Microsoft Excel. 
Documents (510(k)) for assays listed since the year 2000 were examined for test antigen and 
test limitations (Supplementary Table S1).
3. Results
3.1. Test population
In 2014, a total of 818 anti-Toxoplasma IgG tests were performed at IUHPL, with an 
average positivity of 16.4%. The IgG sero-positivity rate was 13.6% (48/354) in females and 
18.2% in males (83/457) (P < 0.01 by student’s t-test). Seven samples did not have gender 
specified, and one of those tested IgG-positive. The highest test volume occurred in patients 
in the sixth decade of life, and sero-positivity increased with age; patients >70 years of age 
had the highest rate of sero-positivity (26%) (Supplementary Fig. S1A,B). Eighty-nine anti-
Toxoplasma-positive serum samples were selected for analysis based on specimen 
availability and sufficient residual volume (≥0.25 ml). The study samples included 38 (43%) 
from females aged 12 to 71 years, and 51 (57%) from males aged 15 to 75.
3.2. Human serum recognizes a diversity of antigens in intracellular tachyzoites
To determine whether IgG sero-positive samples could detect distinct antigens on 
intracellular tachyzoites, we performed immunofluorescence assays with 89 unique ELFA-
positive sera against intracellular parasites grown in Vero cells. As a positive control we used 
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mouse antibodies raised against the Toxoplasma surface antigen SAG1, which has been 
previously described as a dominant antigen in toxoplasmosis (Kasper et al., 1983; Santoro et 
al., 1985). Four ELFA IgG-negative human sera were screened by IFA for use as negative 
controls. One of these specimens demonstrated SAG1-like immune-reactivity while the 
other three were negative and displayed non-specific signal with prolonged exposure times; 
one of these was subsequently used as the negative control for future experiments. Because 
this study was not designed to compare the sensitivity of IFA against intracellular 
tachyzoites with current diagnostics, no further negative sera were tested. All but one of the 
serum test samples (88/89) demonstrated immuno-reactivity against intracellular tachyzoites 
at the dilution tested (1:500). Interestingly, we found a variety of staining patterns when 
using the IgG sero-positive sera (Fig. 1B). The predominant immuno-staining pattern was 
strong staining of the parasite membrane, which is reminiscent of what is seen with SAG1 
antibodies (Fig. 1B - Mouse α-SAG1). Of the 88 samples that stained intracellular parasites, 
84 showed the SAG1-like pattern (Fig. 1B - Human SAG1-like, Table 1). Of those, 24 
showed additional staining including the PVM (Fig. 1B - Human SAG1/PV-like), and 
structures within the PV. Surprisingly, four of the 88 positive samples did not stain the 
tachyzoite membrane and, instead, showed signal consistent with that of proteins localized 
within the PV (Fig. 1B - Human PV-internal). The parasite surface and PV staining patterns 
were confirmed by co-staining with antibodies against SAG1 and the PV localized protein 
GRA7 (Supplementary Fig. S2).
To further characterize the IgG sero-positive sera, two representative samples of the three 
IFA staining pattern types shown in Fig. 1 were also tested by western blot (Fig. 2). All sera 
that exhibited SAG1-like staining by IFA recognized a protein migrating at ~30 kDa (Fig. 2 
black arrowhead), similar to that observed with a mouse anti-SAG1 antibody. Nonetheless, 
in all cases other proteins were detected by the sera, and the 30 kDa protein was not the most 
prominent. This suggests that antibodies against other surface antigens may play a role in the 
human response to toxoplasmosis. On the other hand, sera with a PV-internal-like pattern 
and no IFA reactivity against the parasite surface did not have a detectable band at 30 kDa 
(SAG1) at the tested dilution (Fig. 2D). Interestingly, both of the two independent serum 
samples that showed a PV-internal-like pattern by IFA recognized a common set of three 
proteins (Fig. 2 white arrowheads).
3.3. Sera from Toxoplasma-infected humans recognize bradyzoite cysts
While it is thought that the majority of antibodies generated during toxoplasmosis are 
formed against the tachyzoite stage, we wondered whether sera from IgG sero-positive 
humans would recognize antigens expressed by the encysted bradyzoite stage. Accordingly, 
we induced bradyzoite development in tissue culture and tested the ability of all 89 ELFA-
positive samples to detect encysted parasites by IFA. Interestingly, the majority of sera 
(86/89) demonstrated immuno-reactivity to in vitro bradyzoites by IFA (Table 1, Fig. 3B). 
The major staining pattern was the putative cyst wall, indicating that, although considered 
latent, the bradyzoite cyst can be detected by the immune response. Other staining patterns 
observed were similar to bradyzoite surface staining and cyst matrix (Fig. 3B - Bradyzoite 
surface, Cyst-internal). While the possibilities of remnant SAG1 expression in tissue cultures 
of bradyzoite cysts or of cross-reactivity with SAG1-like antigens cannot be excluded, a 
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mouse SAG1-specific antibody demonstrated no signal against tissue culture bradyzoites as 
expected (data not shown) and anti-Toxoplasma negative sera demonstrated no reactivity to 
in vitro bradyzoites (Fig. 3B - Negative). The different patterns observed with the human 
sera were confirmed by dual immunofluorescence studies using either antibodies against the 
bradyzoite-specific protein BAG1, which stain the individual parasites within the cyst, or 
Dolichos biflorus aglutinnin, which binds to the cyst wall (Supplementary Fig. S3).
3.4. IgM detection of tachyzoites and bradyzoites
Because a selection process occurs during antibody affinity maturation (Eisen, 2014), we 
reasoned there might be different antigens detected by IgM during acute infection compared 
with IgG during chronic infection. To this end, we tested IgM-positive sera for 
immunoreactivity to intracellular tachyzoites and in vitro bradyzoites. Total anti-Toxoplasma 
IgM testing was performed on 341 specimens in 2014 at IUHPL, with 25 of those testing 
positive (7.3%). Remnant serum was available from 18 unique IgM-positive patient samples. 
These were originally determined to be IgM-positive by IFA against extracellular 
tachyzoites with titers from 1:10 to 1:80. Two of these samples also tested positive for anti-
Toxoplasma IgG by ELFA. It is unknown whether any samples had avidity testing 
performed. IgM-positive specimens were from 13 females aged 9 to 59 years, and five males 
aged 6 to 70 years. We used these samples to perform IFA against intracellularly replicating 
tachyzoites and in vitro bradyzoites, and used secondary antibodies specific to human IgG or 
IgM. IgM-specific reactivity towards intracellular tachyzoites was observed in 8/18 
specimens, 8/18 had equivocal reactivity, and 2/18 specimens were negative (Table 2). The 
immunofluorescence patterns by IgM staining were similar to the PVM alone and 
combinations of the PVM/PV-internal/SAG1 (Table 1). While some IgM-positive sera were 
also IgG-positive by IFA, no IgM-specific immuno-reactivity was detected against in vitro 
bradyzoites (Table 2, Fig. 4). One of two IgM-positive specimens that also tested positive for 
IgG by hospital ELFA also showed IgG-specific reactivity against in vitro bradyzoites, with 
a pattern similar to cyst wall (Fig. 4). None of the samples which were IgM-positive/IgG-
negative by clinical diagnostic testing had detectable immunofluorescence against in vitro 
bradyzoites, consistent with an initial antibody response directed against tachyzoites.
4. Discussion
The T. gondii serology tests commercially available in the U.S. have gone through the 
510(k) clearance route by the FDA, which is used for demonstrating substantial equivalence 
between assays. This suggests that despite advances in technology, including automated 
testing platforms and chemiluminescence or fluorescence detection methods, serological 
tests for T. gondii have not changed substantially during the past 30 years. This may be due 
to the acceptable performance of current tests and the challenges in performing clinical 
diagnostic trials for acute and reactivated toxoplasmosis. Nonetheless, the first commercially 
available test for T. gondii IgG avidity admits test performance has not been established for 
prenatal screening, testing in newborns, immunocompromised patients, or in cases of 
reinfection. Further studies with clinical evaluations of performance in these at-risk patient 
populations are needed.
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To improve upon and expand beyond current assays, a more comprehensive understanding 
of antigens for the different stages of the parasite is needed. By testing anti-Toxoplasma 
gondii IgG-positive sera against intracellularly replicating tachyzoites, we observed a variety 
of immuno-staining patterns, which suggests that infected individuals produce antibodies to 
diverse antigens, in addition to SAG1. While the majority of sera tested had immuno-
reactivity similar to SAG1, i.e., surface staining of parasites, a small subset of samples 
demonstrated a staining pattern similar to the PV space. Consistent with this idea, these sera 
also had different band patterns recognized by western blots. Antigens from the 
intravacuolar network and PVM are likely exposed to the immune system upon host cell 
lysis; additionally, dense granule proteins are secreted from both intracellular and 
extracellular parasites (Nam, 2009). Previous studies have demonstrated a protective effect 
for antibodies to dense granule proteins in infected mice (Desolme et al., 2000; Cha et al., 
2001; Jongert et al., 2007). However, it is not known whether the presence of antibodies to 
these antigens has a protective effect in human infection.
One explanation for the diversity of antigenic reactivity could be cross-reactivity with 
antibodies against related parasites. The closest phylogenetic relative to T. gondii, Neospora 
caninum, has not been associated with human infections, however infections occuring in 
domestic or wild animals may lead to human exposure and a serological response (Dubey et 
al., 2007). Few human serological surveys for N. caninum-specific antibodies have been 
conducted and sero-positivity rates from 0% to 38% have been reported in various 
populations (Nam et al., 1998; Petersen et al., 1999; Tranas et al., 1999; Lobato et al., 2006; 
McCann et al., 2008). While we cannot rule out the possibility that observed 
immunoreactivity is due to cross-reacting antibodies specific for N. caninum, previous 
reports have indicated a lack of cross-reactivity between major surface antigens of T. gondii 
and N. caninum (Howe and Sibley, 1999; Zhang et al., 2011).
Recent investigations into antigens suitable for Toxoplasma diagnostic methods have utilized 
multiple approaches including testing for antibodies to secreted antigens and various 
recombinant parasite antigens (Saadatnia et al., 2011; Holec-Gasior, 2013; Khanaliha et al., 
2014). These studies have also demonstrated variable activity between acute and chronic 
infections and, overall, improved sensitivity when multiple antigens are included in the 
assay. As the parasite replicates, it manipulates host cell gene expression to promote nutrient 
acquisition and disrupt the innate immune response (Laliberté and Carruthers, 2008; Blader 
et al., 2015). Thus, it is also possible that the antibodies are detecting host proteins, i.e. are 
auto-antibodies. However, we failed to observe specific reactivity to uninfected host cells at 
the dilution tested by western blot, which suggests the bands recognized are unique to 
infected cells and are either parasite-specific or a host protein that is upregulated in infected 
cells.
Tissue cysts are predominantly found in immune-privileged sites such as the brain and 
skeletal muscle. Here we observed the common presence of anti-bradyzoite antibodies in 
human sera positive for anti-T. gondii IgG. While it is possible immune-reactivity is due to 
shared or related epitopes between stages, the striking differences between IFA patterns 
observed against tachyzoites and in vitro bradyzoites indicates a sufficient level of 
differentiation and recognition of stage-specific antigens. These findings, suggestive of a 
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humoral immune response to tissue cysts, are in contrast to an earlier study which suggested 
a minimal humoral response to the tissue cyst stage (Zhang et al., 1995). More recent 
studies, however, have also detected bradyzoite-specific antibodies from positive sera of 
humans and chronically infected mice (el-Shennawy et al., 2000; Di Cristina et al., 2004). 
DNA vaccine studies have shown a protective effect for surface antigen genes specific to the 
bradyzoite stage, which suggests a bradyzoite-specific response is conducive to controlling 
the chronic stage of the infection in mice (Zhang et al., 2013). Elucidating the contribution 
of the humoral immune response in controlling acute and chronic toxoplasmosis will require 
further work in animal models.
Finally, the observation that anti-Toxoplasma IgM-positive/IgG-negative sera lack antibodies 
to in vitro bradyzoites, in combination with the observation that nearly all of the ELFA anti-
Toxoplasma IgG-positive sera contain antibodies to in vitro bradyzoites, is intriguing. 
However, the small sample size and possible false-positive IgM results limit broad 
generalizations. Inaccuracies with IgM testing have been previously described and inclusion 
of additional IgM antigens may not increase specificity (Wilson et al., 1997; Garry et al., 
2005). The timing of anti-bradyzoite antibody development in humans and the role of 
humoral immunity in controlling latent infection remain open questions for future 
investigation. A study of the timing of antibody development in mice infected orally with 
either oocysts or tissue cysts indicated early responses to sporozoite and bradyzoite antigens 
(Döşkaya et al., 2014). However, it is possible that cyst wall-specific antibodies would not 
develop until later in oral infection as ingested cysts are dissolved by gastrointestinal 
secretions and the parasites rapidly convert into tachyzoites.
Since this study was primarily conducted to investigate the presence of anti-Toxoplasma 
antibodies to additional antigens, study limitations include the absence of additional relevant 
clinical and laboratory findings associated with acute or reactivated toxoplasmosis. These 
include lymphadenitis, imaging studies, pregnancy status, anti-Toxoplasma IgG avidity, HIV 
status, CD4 count, etc. Furthermore, while it is generally assumed that a negative result is 
due to the absence of specific antibodies, another possibility for a negative serology result is 
hypogammaglobunemia. These results offer clinical evidence to support further 
investigations into the utility of incorporating additional parasite antigens in order to 
improve detection of parasite-specific antibodies and to determine if the detection of anti-
bradyzoite antibodies can serve as a useful tool to distinguish between acute and chronic 
toxoplasmosis. Additional studies, including identification of target antigens and testing the 
recognition of recombinant proteins with well-characterized sera, are needed to demonstrate 
the clinical utility of expanding the targets included in diagnostic assays.
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Highlights
• We screened anti-Toxoplasma gondii IgG+ or IgM+ human sera for detection 
of additional antigens.
• Anti-T. gondii IgG+ sera showed immune reactivity to intracellular 
tachyzoites.
• The IgG+ sera were also immune-reactive to in vitro induced bradyzoites.
• Immune reactivity to in vitro bradyzoites was not observed in IgM+/IgG− 
sera.
• Future investigations of these antigens are needed to demonstrate clinical 
utility.
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Fig. 1. 
Human sera positive for anti-Toxoplasma antibodies demonstrate a variety of immuno-
fluorescence patterns against intracellular tachyzoites by indirect immunofluorescence (red 
fluorescence, goat anti-human IgG AF594; blue fluorescence, DAPI). (A) Diagram of 
tachyzoite-infected cell with arrows indicating immune-reactive structures: N, host cell 
nucleus; PV, parasitophorous vacuole; PVM, PV membrane; SAG1, surface antigen 
glycoprotein1. (B) Representative images of each staining pattern are shown. Some sera had 
combinations of the above patterns (Table 1). Estimated scale bar = 4 αm.
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Fig. 2. 
Human sera demonstrating different IFA patterns were observed to have different patterns by 
western blot. Two sera with representative IFA patterns were tested by western blot against 
uninfected cells and cells infected with Toxoplasma tachyzoites. (A) Mouse anti-SAG1 
(MsSAG1) and uninfected mouse sera (MsNeg). (B) Human sera with SAG1-like IFA. (C) 
Human sera with SAG1-like and parasitophorous vacuole (PV) IFA. (D) Human sera with 
PV-internal IFA. Black arrowheads indicate potential SAG1 (p30) bands; white arrowheads 
indicate bands common to PV-internal-like staining. Molecular mass indicated in kDa.
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Fig. 3. 
Indirect immunofluorescence with human sera (Hs) positive for anti-Toxoplasma antibodies 
demonstrates a variety of immuno-fluorescence patterns against in vitro bradyzoites. In vitro 
bradyzoites detected with GFP fluorescence (under the control of a bradyzoite-specific 
promoter (ldh2); red fluorescence, goat anti-human IgG AF594; blue fluorescence, DAPI). 
(A) Diagram of bradyzoite-infected cell with arrows indicating immuno-reactive structures; 
N, host cell nucleus. (B) Representative images of three staining patterns from three positive 
sera and one negative sera are shown. Cyst wall, structure enclosing bradyzoites; bradyzoite-
surface, bradyzoite cell surface; cyst-internal, structures inside the cyst wall and outside the 
bradyzoites. Some sera had combinations of the above staining patterns (Table 1). Estimated 
scale bar = 4 αm.
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Fig. 4. 
Representative images of IFA with two human sera (A, B) that demonstrated IgM- and IgG-
positive immunoreactivity against intracellular tachyzoites as well as IgG-positive reactivity 
to in vitro bradyzoites. Primary antibody, human serum; secondary anti-sera (goat, Gt) 
specific for human IgM or IgG (red fluorescence, goat anti-human IgG AF594 or goat anti-
human IgM AF594; green fluorescence, GFP; blue fluorescence, DAPI). Estimated scale bar 
= 4 αm.
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Table 1
Combinations of immunofluorescence patterns directed towards tachyzoites and in vitro bradyzoites by human 
serum positive for anti-Toxoplasma gondii IgG antibodies.
Tachyzoite Bradyzoite N (%)
Tz surface Bz surface/cyst wall/cyst internal 41 (46.1)
Tz surface/PVM/PV - internal Bz surface/cyst wall/cyst internal 14 (15.7)
Tz surface Bz surface 12 (13.5)
Tz surface cyst wall 7 (7.9)
Tz surface/PVM/PV - internal cyst wall 6 (6.7)
PV-internal cyst wall 3 (3.4)
Tz surface/PVM/PV - internal Bz surface 2 (2.2)
Tz surface negative/equivocal 2 (2.2)
PV-internal Bz surface 1 (1.1)
negative/equivocal negative/equivocal 1 (1.1)
Total 89 (100)
Tz, tachyzoite; Bz, bradyzoite; PV, parasitophorous vacuole; PVM, PV membrane.
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